Loading…
← CockpitCompetitor Analysis › ZEAL.CO Zealand Pharma A/SOpen in the cockpit ↗

Zealand Pharma A/SZEAL.COCompetitor analysis, valuation and peers

Denmark · DKK·Health Care›Biotechnology

Develops peptide-based drugs, including treatments for short bowel syndrome and obesity/metabolic disease.

Momentum laggard 3
Mkt cap
$2.16B
US dollars, full cap
Free float
88%
of shares outstanding
$/day
$13.5M
20-day average traded
Fwd P/E
7.2×
forward earnings
ROIC−WACC
+32.2 pp
WACC 7.1%
Hurdle
n/a
no reverse DCF
Next earnings
99 days
25 Feb 2027
Close · DKKDKK 221.70
1D-3.4%
1W-9.6%
1M-3.5%
3M-31.0%
6M-30.3%
YTD-52.5%
1Y-57.4%
ATR %3.9%
52w lowhigh60.1% off high

What Zealand Pharma A/S does

Develops peptide-based drugs, including treatments for short bowel syndrome and obesity/metabolic disease.

Earns mainly through partners, which pay upfront and milestone fees and royalties on drugs Zealand discovered, such as Boehringer Ingelheim's survodutide, a weight-loss candidate, and a collaboration with Roche on the amylin analogue petrelintide. It keeps development of some rare-disease products for itself.

Products and services

  • Glepaglutide (short bowel syndrome)
  • Obesity/metabolic pipeline (GLP-1 based)
  • Partnered programs (e.g., with Boehringer Ingelheim)

Customers

  • Specialty pharma partners (licensing)
  • Gastroenterologists/endocrinologists via partners

Where it sits in the supply chain

  • Biopharmaceuticals
  • Peptide drug discovery & development
  • Clinical-stage + partnered commercial…

What could go right

  • GLP-1/obesity drug market boom
  • Partnership milestone/royalty income

What could go wrong

  • Clinical trial failure risk
  • Dependent on partners for late-stage funding/commercialization

Moat: narrow (IP / patents, process know-how). Deep expertise in peptide drug design gives a pipeline of differentiated candidates and pharma partnerships.

Headquarters: Copenhagen, Denmark · Founded: 1998 · Employees: 481

Named competitors

Zealand Pharma A/S at a glance

Size Zealand Pharma A/S (ZEAL.CO) is a Denmark Health Care company (Biotechnology) with a market value of $2.16B, the 32nd largest of 60 Denmark companies the cockpit tracks. Shares closed at DKK 221.70 on 18 Nov 2026.

Performance Over six months the shares fell 30.3%, against -10.8% for the median peer and +6.3% for the Denmark market (cap-weighted) — 4th lowest of 20 in its peer set.

Growth Revenue fell 49.8% over the last twelve months (peer median +4.1%); the operating margin is 46.2% (peer median -19.9%).

Valuation It trades at 7.2× forward earnings against a peer median of 38.4× (cheapest of 6).

Capital Return on invested capital runs 32.2 points above its cost of capital (7.1% WACC).

Next results Next results expected around 25 Feb 2027 (exchange calendar; dates can move).

Relative performance

8010012021 May 202621 Aug 202618 Nov 2026Peer median 92ZEAL.CO 69
Six months, rebased to 100: Zealand Pharma A/S against the median of its 20 peers (local-currency closes).

Zealand Pharma A/S financials

Reported figures in DKK; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
RevenueDKK 4.60BDKK 9.21BDKK 62.7MDKK 343MDKK 104M
Revenue growth—+14,599%-82%+230%—
Gross profitDKK 4.56BDKK 9.19BDKK 29.0MDKK 295MDKK 73.3M
EBITDADKK 2.17BDKK 7.18B-DKK 1.24B-DKK 533M-DKK 749M
Net incomeDKK 3.09BDKK 6.46B-DKK 1.08B-DKK 704M-DKK 966M
Free cash flow-DKK 1.53BDKK 6.50B-DKK 941M-DKK 437M-DKK 954M
Capital expenditureDKK 86.9MDKK 69.1MDKK 13.1MDKK 23.7MDKK 11.7M
Total debtDKK 484MDKK 406MDKK 392MDKK 200MDKK 524M

Quarterly statements and history in the cockpit →

Zealand Pharma A/S competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

0%+100%+200%+300%0%+50%CLDXBEAMPVLA300676ALMRPHVS302440RCUS300255TRVIMRVIREPLZEAL.CO6-month return →1-month return →
Up and to the right = strong over both horizons. Zealand Pharma A/S is the large dot.

Fundamentals: revenue growth against valuation

-50%0%+50%0×100×200×300×300676VIMIANAUPH300142BCRXZEAL.CORevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Zealand Pharma A/S is the large dot.

Zealand Pharma A/S competitors and peer comparison

Head to head with its named competitors (ZEAL.CO vs NOVO-B.CO vs LLY vs AMGN)
CompanyMarket cap6M returnRevenue growthOp. marginForward P/EReq g
Zealand Pharma A/S ZEAL.CO$2.16B-30%-50%46%7.2×n/a
Novo Nordisk A/S NOVO-B.CO$177B-6%+6%48%11.8×-0.5%
Lilly (Eli) LLY$1.30T+36%+46%51%29.5×6.5%
Amgen AMGN$240B+34%+9%36%18.3×1.6%

How Zealand Pharma A/S compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Zealand Pharma A/S against its 20 peers (data as of 18 Nov 2026)
MeasureZEAL.COPeer medianRank in peer set
1-month return-3.5%-7.2%10th highest of 21
6-month return-30.3%-10.8%4th lowest of 20
Distance from 52-week high-60.1%-34.1%2nd lowest of 21
Revenue growth (TTM)-49.8%+4.1%5th lowest of 17
Operating margin46.2%-19.9%2nd highest of 15
Forward P/E7.2×38.4×cheapest of 6
ROIC minus cost of capital+32.2 pp-11.6 pp3rd highest of 11
EV / EBITDA0.8×9.8×cheapest of 4
Net debt / EBITDA-6.0×1.4×least indebted of 5

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
Zealand Pharma A/S ZEAL.CODenmark$2.16B-30%-50%46%7.2×n/an/a
Celldex Therapeutics CLDXUnited States$2.16B-11%-94%-211,685%n/an/an/a
Beam Therapeutics BEAMUnited States$2.17B-22%+163%-268%n/an/an/a
Palvella Therapeutics PVLAUnited States$2.14B+27%-100%n/an/an/an/a
BGI Genomics 300676.SZChina$2.13B-15%0%-14%126.7×n/an/a
Alamar Biosciences ALMRUnited States$2.12B+51%+195%-42%n/an/an/a
Pharvaris PHVSUnited States$2.21B+7%n/an/an/an/an/a
Evopoint Biosciences 688837.SSChina$2.08Bn/an/an/an/an/an/a
SKBS 302440.KSSouth Korea$2.25B-12%+11%-23%n/an/an/a
Vimian VIMIAN.STSweden$2.26B+51%+8%19%38.4×13.4%+44.5%
Lakefront Biotherapeutics LKFT.ASNetherlands$2.26B+31%+223%64%n/an/an/a
Arcus Biosciences RCUSUnited States$2.27B-34%-58%-475%n/an/an/a
Aurinia Pharmaceuticals AUPHUnited States$2.03B-5%+21%45%18.1×3.5%+41.4%
Hebei Changshan Biochemical Pharmaceutical 300255.SZChina$2.33B-59%0%-25%n/an/an/a
Immunome IMNMUnited States$1.98B-22%-100%n/an/an/an/a
Trevi Therapeutics TRVIUnited States$1.93B-3%n/an/an/an/an/a
Maravai Lifesciences MRVIUnited States$1.92B+101%+11%-17%n/an/an/a
Sinocelltech 688520.SSChina$1.90B-35%-40%-75%n/an/an/a
Walvax Biotechnology 300142.SZChina$2.48B-26%-23%5%348.7×29.5%-3.8%
BioCryst Pharmaceuticals BCRXUnited States$1.88B-16%+60%42%11.1×-11.0%+117.9%
Replimune REPLUnited States$1.88B+321%n/an/an/an/an/a

Questions

Who are Zealand Pharma A/S's main competitors?
Named competitors: Novo Nordisk (NOVO-B.CO), Eli Lilly (LLY), Amgen (AMGN). The cockpit's measured peer set (industry) also includes Celldex Therapeutics (CLDX), Beam Therapeutics (BEAM), Palvella Therapeutics (PVLA), BGI Genomics (300676.SZ), Alamar Biosciences (ALMR), Pharvaris (PHVS).
Is Zealand Pharma A/S expensive compared with its peers?
On forward p/e it trades at 7.2× against a peer median of 38.4×, cheapest of 6 in its peer set.
How has Zealand Pharma A/S stock performed?
Over six months to 18 Nov 2026 the shares returned -30.3% against -10.8% for the median peer; over one year -57.4%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.